TNFRSF9 and neoplasm: To address this issue, Claus et al. introduced a 2 + 1-type design that successfully assembled trimeric 4-1BBL on an antibody backbone, demonstrating that clustering three 4-1BB receptors at the tumor site maximized 4-1BB agonism (Claus et al., 2019).